12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sativex: Phase III started

GW and partner Otsuka began a 2-part Phase III trial to evaluate twice-daily Sativex for up to 10 sprays per day in patients with advanced cancer who have inadequate analgesia even with optimized chronic opioid therapy. The single-blind first part will evaluate Sativex for 2 weeks in about 540 patients. In the double-blind second part, patients who respond to treatment will be randomized to...

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >